-
1
-
-
0035901579
-
The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
-
Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001 (Pubitemid 32322245)
-
(2001)
Annals of Internal Medicine
, vol.134
, Issue.8
, pp. 663-694
-
-
Lepage, L.1
Altman, D.G.2
Schulz, K.F.3
Moher, D.4
Egger, M.5
Davidoff, F.6
Elbourne, D.7
Gotzsche, P.C.8
Lang, T.9
-
2
-
-
0035906308
-
The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
-
Moher D, Schulz KF, Altman D: The CONSORT statement: Revised recommendations for improving the quality of reports of parallelgroup randomized trials. JAMA 285:1987-1991, 2001 (Pubitemid 32366951)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.15
, pp. 1987-1991
-
-
Moher, D.1
Schulz, K.F.2
Altman, D.3
-
3
-
-
0035941525
-
Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas
-
Ioannidis JP, Lau J: Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 285:437-443, 2001 (Pubitemid 32097262)
-
(2001)
Journal of the American Medical Association
, vol.285
, Issue.4
, pp. 437-443
-
-
Ioannidis, J.P.A.1
Lau, J.2
-
4
-
-
8744229000
-
Better reporting of harms in randomized trials: An extension of the CONSORT statement
-
Ioannidis JP, Evans SJ, Gøtzsche PC, et al: Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 141:781-788, 2004 (Pubitemid 39524916)
-
(2004)
Annals of Internal Medicine
, vol.141
, Issue.10
, pp. 781-788
-
-
Ioannidis, J.P.A.1
Evans, S.J.W.2
Gotzsche, P.C.3
O'Neill, R.T.4
Altman, D.G.5
Schulz, K.6
Moher, D.7
-
5
-
-
10744228140
-
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
-
DOI 10.1016/S1053-4296(03)00031-6
-
Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181, 2003 (Pubitemid 36962641)
-
(2003)
Seminars in Radiation Oncology
, vol.13
, Issue.3
, pp. 176-181
-
-
Trotti, A.1
Colevas, A.D.2
Setser, A.3
Rusch, V.4
Jaques, D.5
Budach, V.6
Langer, C.7
Murphy, B.8
Cumberlin, R.9
Coleman, C.N.10
Rubin, P.11
-
6
-
-
84865165918
-
The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs
-
Niraula S, Seruga B, Ocana A, et al: The price we pay for progress: A meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol 30:3012-3019, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 3012-3019
-
-
Niraula, S.1
Seruga, B.2
Ocana, A.3
-
8
-
-
21544455512
-
Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease
-
Ethgen M, Boutron I, Baron G, et al: Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med 143:20-25, 2005 (Pubitemid 40923331)
-
(2005)
Annals of Internal Medicine
, vol.143
, Issue.1
, pp. 20-25
-
-
Ethgen, M.1
Boutron, I.2
Baron, G.3
Giraudeau, B.4
Sibilia, J.5
Ravaud, P.6
-
9
-
-
54849184800
-
Published randomized controlled trials of drug therapy for dementia often lack complete data on harm
-
Lee PE, Fischer HD, Rochon PA, et al: Published randomized controlled trials of drug therapy for dementia often lack complete data on harm. J Clin Epidemiol 61:1152-1160, 2008
-
(2008)
J Clin Epidemiol
, vol.61
, pp. 1152-1160
-
-
Lee, P.E.1
Fischer, H.D.2
Rochon, P.A.3
-
10
-
-
33947266027
-
Reporting adverse events in randomized controlled trials
-
DOI 10.1002/pds.1310
-
Nuovo J, Sather C: Reporting adverse events in randomized controlled trials. Pharmacoepidemiol Drug Saf 16:349-351, 2007 (Pubitemid 46431697)
-
(2007)
Pharmacoepidemiology and Drug Safety
, vol.16
, Issue.3
, pp. 349-351
-
-
Nuovo, J.1
Sather, C.2
-
11
-
-
70350489859
-
Reporting of safety results in published reports of randomized controlled trials
-
Pitrou I, Boutron I, Ahmad N, et al: Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 169:1756-1761, 2009
-
(2009)
Arch Intern Med
, vol.169
, pp. 1756-1761
-
-
Pitrou, I.1
Boutron, I.2
Ahmad, N.3
-
12
-
-
84905831456
-
Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on quality of treatment related harms reporting: An analysis of National Cancer Institute's Co-Operative Group phase III randomized controlled trials
-
abstr 673
-
Mhaskar R, Wao H, Reljic T, et al: Impact of National Cancer Institute's Common Toxicity Criteria and Common Terminology Criteria for Adverse Events on quality of treatment related harms reporting: An analysis of National Cancer Institute's Co-Operative Group phase III randomized controlled trials. Blood 118, 2011 (abstr 673)
-
(2011)
Blood
, vol.118
-
-
Mhaskar, R.1
Wao, H.2
Reljic, T.3
-
13
-
-
84905831447
-
Impact of quality of reporting of treatment-related harms on overall therapeutic effects
-
Presented at the (abstr 73)
-
Mhaskar R, Reljic T, Wao H, et al: Impact of quality of reporting of treatment-related harms on overall therapeutic effects. Presented at the 20th Cochrane Colloquium, Auckland, New Zealand, October 1, 2012 (abstr 73)
-
20th Cochrane Colloquium, Auckland, New Zealand, October 1, 2012
-
-
Mhaskar, R.1
Reljic, T.2
Wao, H.3
-
14
-
-
33748446657
-
Adverse event reporting in publications compared with sponsor database for cancer clinical trials
-
DOI 10.1200/JCO.2005.05.3959
-
Scharf O, Colevas AD: Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 24:3933-3938, 2006 (Pubitemid 46630741)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.24
, pp. 3933-3938
-
-
Scharf, O.1
Colevas, A.D.2
-
15
-
-
84875139810
-
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
-
Vera-Badillo FE, Shapiro R, Ocana A, et al: Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer. Ann Oncol 24:1238-1244, 2013
-
(2013)
Ann Oncol
, vol.24
, pp. 1238-1244
-
-
Vera-Badillo, F.E.1
Shapiro, R.2
Ocana, A.3
-
16
-
-
33644831407
-
Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials
-
Mahoney MR, Sargent DJ, O'Connell MJ, et al: Dealing with a deluge of data: An assessment of adverse event data on North Central Cancer Treatment Group trials. J Clin Oncol 23:9275-9281, 2005
-
(2005)
J Clin Oncol
, vol.23
, pp. 9275-9281
-
-
Mahoney, M.R.1
Sargent, D.J.2
O'Connell, M.J.3
-
17
-
-
66649132782
-
Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate
-
Dorr DA, Burdon R, West DP, et al: Quality of reporting of serious adverse drug events to an institutional review board: A case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res 15:3850-3855, 2009
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3850-3855
-
-
Dorr, D.A.1
Burdon, R.2
West, D.P.3
-
18
-
-
34249676430
-
Evaluation of serious adverse drug reactions: A Proactive Pharmacovigilance Program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers
-
DOI 10.1001/archinte.167.10.1041
-
Bennett CL, Nebeker JR, Yarnold PR, et al: Evaluation of serious adverse drug reactions: A proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med 167:1041-1049, 2007 (Pubitemid 46835792)
-
(2007)
Archives of Internal Medicine
, vol.167
, Issue.10
, pp. 1041-1049
-
-
Bennett, C.L.1
Nebeker, J.R.2
Yarnold, P.R.3
Tigue, C.C.4
Dorr, D.A.5
McKoy, J.M.6
Edwards, B.J.7
Hurdle, J.F.8
West, D.P.9
Lau, D.T.10
Angelotta, C.11
Weitzman, S.A.12
Belknap, S.M.13
Djulbegovic, B.14
Tallman, M.S.15
Kuzel, T.M.16
Benson, A.B.17
Evens, A.18
Trifilio, S.M.19
Courtney, D.M.20
Raisch, D.W.21
more..
-
19
-
-
39649101923
-
Is there room for improvement in adverse event reporting in the era of targeted therapies?
-
DOI 10.1093/jnci/djm324
-
Edgerly M, Fojo T: Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100:240-242, 2008 (Pubitemid 351480535)
-
(2008)
Journal of the National Cancer Institute
, vol.100
, Issue.4
, pp. 240-242
-
-
Edgerly, M.1
Fojo, T.2
-
20
-
-
84870720349
-
Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology
-
Basch E, Abernethy AP, Mullins CD, et al: Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30:4249-4255, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 4249-4255
-
-
Basch, E.1
Abernethy, A.P.2
Mullins, C.D.3
-
21
-
-
56649123212
-
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis
-
Nalluri SR, Chu D, Keresztes R, et al: Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 300:2277-2285, 2008
-
(2008)
JAMA
, vol.300
, pp. 2277-2285
-
-
Nalluri, S.R.1
Chu, D.2
Keresztes, R.3
-
22
-
-
79551520348
-
Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis
-
Ranpura V, Hapani S, Wu S: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
-
(2011)
JAMA
, vol.305
, pp. 487-494
-
-
Ranpura, V.1
Hapani, S.2
Wu, S.3
|